|drug2887||Retrospective case-control analysis Wiki||0.71|
|D012128||Respiratory Distress Syndrome, Adult NIH||0.11|
|D012127||Respiratory Distress Syndrome, Newborn NIH||0.06|
There are 2 clinical trials
The SARS-Cov2 viral pandemic is responsible for a new infectious disease called COVID-19 (CoronaVIrus Disease), is a major health problem. Respiratory complications occur in 15 to 40%, the most serious is acute respiratory distress syndrome (ARDS). The management of COVID-19 is essentially symptomatic with respiratory oxygen supplementation in mild forms to invasive mechanical ventilation in the most severe forms. Prone position (PP) reduced mortality in patients with ARDS in intensive care. Ding et al showed that PP and high flow oxygenation reduced the intubation in patients with moderate to severe ARDS. The investigators hypothesize that the use of PP in spontaneously ventilation patients under oxygen standard could decrease incidence of intubation or non-invasive ventilation or death compared to conventional positioning management in medical departments.
Description: To show that PP in spontaneously ventilation patients could reduce the risk of acquiring the following event (composite endpoint): Endotracheal intubation Or non-invasive ventilation (NIV) with two pressure levels And/or deathMeasure: Percent age of patients who will have endotracheal intubation or non-invasive ventilation at two pressure levels and/or die, in each of the 2 randomization groups. Time: Day 28
Description: Show that the use of prone position improves the WHO ordinal scale score by 2 points faster (after randomization)Measure: Duration in days for the change of 2 points on the WHO ordinal scale Time: Day 28
Description: Show that prone position with spontaneous ventilation reduces the need for endotracheal intubation and invasive mechanical ventilationMeasure: Rate (%) of intubation and invasive ventilation in the 2 randomization groups. Time: Day 28
Description: Show that prone position with spontaneous ventilation reduces the use of non-invasive ventilation at two pressure levelsMeasure: Rate (%) of non-invasive ventilation at two pressure levels in the 2 randomization groups Time: Day 28
Description: Show that prone position in spontaneous ventilation reduces the time under oxygen therapy.Measure: Duration of oxygen therapy in the 2 randomization groups. Time: Day 28
Description: Show that prone position reduces the length of hospitalization.Measure: Duration of hospitalization in the 2 randomization groups. Time: Day 28
Description: Compare the hospital mortality of the 2 groupsMeasure: Hospital mortality and mortality at D28 in the 2 randomization groups Time: Day 28
Description: Compare the incidence of the need for resuscitation transfer between the two groups.Measure: Rate (%) of need for transfer to intensive care unit Time: Day 28
Description: Compare the impact of the use of non-invasive ventilation and intubation on the entire hospital stay when the hospital stay is longer than 28 days between the two groups.Measure: Rate (%) of use of non-invasive ventilation at two pressure levels, intubation throughout the entire stay when the stay is longer than 28 days. Time: 1 year
the purpose of this study to evaluate the effect of early awake PP (prone position)application on oxygenation and intubation requirement in patients with acute respiratory failure due to coronavirus disease 2019 pneumonia.
Description: the duration of icu stay dayMeasure: intensive care unit stay Time: up to 28 days
Description: mortality percentMeasure: short term mortality Time: up to 28 days
Description: partial oxygen pressure: mmhg , partial carbondiocsit pressure mmhgMeasure: blood gases Time: up to 24 hours
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.Drug Reports MeSH Reports HPO Reports